1. In Vivo

BlueRock Therapeutics: Sizing Up The Regenerative Power Of Cells

An Interview With CEO Emile Nuwaysir

 
• By William Looney

Bayer's novel 2016 joint venture with the venture capital group Versant Ventures has spawned something like a big pharma, new science start-up, with an open mandate to disrupt drug development through generous endowments in the scarce commodities of freedom, time and patience.

Nuwaysir_Emile
Emile Nuwaysir, CEO of BlueRock Therapeutics

In Vivo talks to the CEO of BlueRock Therapeutics, Emile Nuwaysir, the exemplar of this new approach, which Bayer AG is trusting to strengthen its cardiovascular and neurodegenerative portfolio through the hard science of induced cell repair and restoration.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

More from Leadership